Keros Therapeutics Future Growth
Future criteria checks 2/6
Keros Therapeutics's earnings are forecast to decline at 6.3% per annum while its annual revenue is expected to grow at 27.3% per year. EPS is expected to grow by 0.7% per annum.
Key information
-6.3%
Earnings growth rate
0.7%
EPS growth rate
| Biotechs earnings growth | 27.7% |
| Revenue growth rate | 27.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff
Dec 12We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Nov 20
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Aug 07Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?
Nov 27Keros Therapeutics prices equity offering at $50
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6 | -202 | -218 | -219 | 11 |
| 12/31/2025 | 33 | -147 | -170 | -179 | 14 |
| 12/31/2024 | 30 | -165 | -197 | -153 | 14 |
| 9/30/2024 | 1 | -182 | -143 | -140 | N/A |
| 6/30/2024 | 0 | -168 | -146 | -144 | N/A |
| 3/31/2024 | 0 | -160 | -137 | -135 | N/A |
| 12/31/2023 | 0 | -153 | -127 | -125 | N/A |
| 9/30/2023 | 0 | -142 | -123 | -120 | N/A |
| 6/30/2023 | N/A | -127 | -113 | -111 | N/A |
| 3/31/2023 | N/A | -116 | -105 | -103 | N/A |
| 12/31/2022 | N/A | -105 | -71 | -70 | N/A |
| 9/30/2022 | 20 | -82 | -69 | -68 | N/A |
| 6/30/2022 | 20 | -79 | -59 | -58 | N/A |
| 3/31/2022 | 20 | -67 | -54 | -53 | N/A |
| 12/31/2021 | 20 | -59 | -63 | -62 | N/A |
| 9/30/2021 | 0 | -61 | -51 | -51 | N/A |
| 6/30/2021 | 0 | -53 | -48 | -47 | N/A |
| 3/31/2021 | N/A | -49 | -40 | -39 | N/A |
| 12/31/2020 | N/A | -45 | -37 | -37 | N/A |
| 9/30/2020 | 3 | -39 | -35 | -34 | N/A |
| 6/30/2020 | 5 | -31 | -27 | -26 | N/A |
| 3/31/2020 | 8 | -23 | -22 | -22 | N/A |
| 12/31/2019 | 10 | -14 | -16 | -16 | N/A |
| 12/31/2018 | 10 | -2 | 7 | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KROS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KROS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KROS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KROS's revenue (27.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: KROS's revenue (27.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KROS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:39 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Keros Therapeutics, Inc. is covered by 19 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Jason Zemansky | BofA Global Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |